Pulmonx (NASDAQ:LUNG) Insider Sells $32,193.70 in Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Srikanth Radhakrishnan sold 14,245 shares of the stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $32,193.70. Following the sale, the insider directly owned 316,994 shares in the company, valued at approximately $716,406.44. The trade was a 4.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Trading Down 2.2%

Shares of LUNG stock opened at $2.21 on Friday. The stock has a 50 day simple moving average of $1.82 and a 200-day simple moving average of $1.57. Pulmonx Corporation has a 1-year low of $1.13 and a 1-year high of $2.89. The company has a market cap of $94.92 million, a price-to-earnings ratio of -1.91 and a beta of 0.34. The company has a debt-to-equity ratio of 0.95, a current ratio of 4.32 and a quick ratio of 3.52.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. The firm had revenue of $22.76 million during the quarter, compared to the consensus estimate of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. On average, equities research analysts expect that Pulmonx Corporation will post -1.05 EPS for the current fiscal year.

Key Headlines Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Analyst sentiment remains broadly favorable, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus. The average price target of $7.67 is substantially above recent trading levels, suggesting significant potential upside if Pulmonx delivers on its growth plans. Pulmonx analyst and earnings information
• Positive Sentiment: Pulmonx’s latest quarterly results exceeded expectations: revenue was $22.76 million versus the $22.39 million consensus estimate, while its loss of $0.24 per share was narrower than the expected $0.28 loss. Pulmonx quarterly results
• Neutral Sentiment: CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan sold a combined 78,340 shares at approximately $2.26 per share. The filings say the transactions covered tax-withholding obligations related to vested equity awards, reducing their significance as a signal of declining confidence; however, the sales may add modest short-term supply. Pulmonx insider sales report
• Negative Sentiment: Recent gains have triggered profit-taking, contributing to the stock’s retreat and weakening short-term trading sentiment. Pulmonx shares fall following recent gains
• Negative Sentiment: Pulmonx remains unprofitable, and analysts expect a full-year loss of roughly $1.05 per share. The company’s negative margins and uncertain path to sustained profitability are keeping investors cautious despite the earnings beat. Pulmonx profit-taking and earnings outlook

Analyst Upgrades and Downgrades

LUNG has been the topic of a number of research reports. Weiss Ratings upgraded Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Wall Street Zen upgraded shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $7.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. R Squared Ltd acquired a new stake in Pulmonx during the first quarter worth about $26,000. Cerity Partners LLC purchased a new stake in shares of Pulmonx in the 4th quarter valued at approximately $27,000. Opal Capital LLC acquired a new stake in shares of Pulmonx during the 4th quarter worth approximately $29,000. Jain Global LLC purchased a new stake in shares of Pulmonx during the 3rd quarter valued at approximately $30,000. Finally, Sei Investments Co. acquired a new position in Pulmonx in the first quarter valued at approximately $31,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.